Show simple item record

Aggression, anxiety and vocalizations in animals: GABA A and 5-HT anxiolytics

dc.contributor.authorBarros, H. M.en_US
dc.contributor.authorMiczek, K. A.en_US
dc.contributor.authorWeerts, E. M.en_US
dc.contributor.authorVivian, Jeffrey A.en_US
dc.date.accessioned2006-09-11T17:40:39Z
dc.date.available2006-09-11T17:40:39Z
dc.date.issued1995-09en_US
dc.identifier.citationMiczek, K. A.; Weerts, E. M.; Vivian, J. A.; Barros, H. M.; (1995). "Aggression, anxiety and vocalizations in animals: GABA A and 5-HT anxiolytics." Psychopharmacology 121(1): 38-56. <http://hdl.handle.net/2027.42/46351>en_US
dc.identifier.issn0033-3158en_US
dc.identifier.issn1432-2072en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/46351
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=8539340&dopt=citationen_US
dc.description.abstractA continuing challenge for preclinical research on anxiolytic drugs is to capture the affective dimension that characterizes anxiety and aggression, either in their adaptive forms or when they become of clinical concern. Experimental protocols for the preclinical study of anxiolytic drugs typically involve the suppression of conditioned or unconditioned social and exploratory behavior (e.g., punished drinking or social interactions) and demonstrate the reversal of this behavioral suppression by drugs acting on the benzodiazepine-GABA A complex. Less frequently, aversive events engender increases in conditioned or unconditioned behavior that are reversed by anxiolytic drugs (e.g., fear-potentiated startle). More recently, putative anxiolytics which target 5-HT receptor subtypes produced effects in these traditional protocols that often are not systematic and robust. We propose ethological studies of vocal expressions in rodents and primates during social confrontations, separation from social companions, or exposure to aversive environmental events as promising sources of information on the affective features of behavior. This approach focusses on vocal and other display behavior with clear functional validity and homology. Drugs with anxiolytic effects that act on the benzodiazepine-GABA A receptor complex and on 5-HT 1A receptors systematically and potently alter specific vocalizations in rodents and primates in a pharmacologically reversible manner; the specificity of these effects on vocalizations is evident due to the effectiveness of low doses that do not compromise other physiological and behavioral processes. Antagonists at the benzodiazepine receptor reverse the effects of full agonists on vocalizations, particularly when these occur in threatening, startling and distressing contexts. With the development of antagonists at 5-HT receptor subtypes, it can be anticipated that similar receptor-specificity can be established for the effects of 5-HT anxiolytics.en_US
dc.format.extent2955128 bytes
dc.format.extent3115 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherSpringer-Verlagen_US
dc.subject.otherBenzodiazepine Receptorsen_US
dc.subject.otherStressen_US
dc.subject.otherPainen_US
dc.subject.otherExploratory Behavioren_US
dc.subject.otherDefenseen_US
dc.subject.otherBenzodiazepinesen_US
dc.subject.otherBiomedicineen_US
dc.subject.otherPsychiatryen_US
dc.subject.otherPharmacology/Toxicologyen_US
dc.subject.otherPunishmenten_US
dc.subject.otherStartleen_US
dc.subject.otherDominanceen_US
dc.subject.otherAggressionen_US
dc.subject.otherAnxiolyticsen_US
dc.subject.other5-HT Agonistsen_US
dc.subject.other5-HIAAen_US
dc.subject.otherVocalizationsen_US
dc.subject.otherSocial Behavioren_US
dc.subject.otherMaternal Behavioren_US
dc.subject.otherOpiatesen_US
dc.subject.otherUltrasoundsen_US
dc.titleAggression, anxiety and vocalizations in animals: GABA A and 5-HT anxiolyticsen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelPsychiatryen_US
dc.subject.hlbsecondlevelNeurosciencesen_US
dc.subject.hlbsecondlevelChemistryen_US
dc.subject.hlbsecondlevelBiological Chemistryen_US
dc.subject.hlbtoplevelScienceen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumResearch Building, Tufts University, 490 Boston Ave, 02155, Medford, MA, USA; Department of Pharmacology, University of Michigan Medical School, 1301 Medical Science Research Building III, 48109-0632, Ann Arbor, MI, USAen_US
dc.contributor.affiliationotherResearch Building, Tufts University, 490 Boston Ave, 02155, Medford, MA, USA; Division of Behavioral Biology, Johns Hopkins University School of Medicine, Hopkins Bayview Research Campus, 21224-6823, Baltimore, MD, USAen_US
dc.contributor.affiliationotherResearch Building, Tufts University, 490 Boston Ave, 02155, Medford, MA, USAen_US
dc.contributor.affiliationotherResearch Building, Tufts University, 490 Boston Ave, 02155, Medford, MA, USAen_US
dc.contributor.affiliationumcampusAnn Arboren_US
dc.identifier.pmid8539340en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/46351/1/213_2005_Article_BF02245590.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1007/BF02245590en_US
dc.identifier.sourcePsychopharmacologyen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.